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Because human lymphotoxin (LT) was originally isolated from a lymphoblastoid cell line, we 
investigated the role of this molecule in three newly established Epstein-Barr virus (EBV)-infected 
human  B  cell  lines.  These  lines  were  derived  from  acute  lymphoblastic leukemia  (Z-6), 
myelodysplastic syndrome (Z-43),  and acute myelogenous leukemia (Z-55) patients who had a 
prior EBV infection. Each lymphoblastoid cell line had a karyotype that was different from that 
of the original parent leukemic cells, and all expressed B cell, but not T cell or myeloid surface 
markers.  In all three lines, rearranged immunoglobulin heavy chain joining region (J.) bands 
were found, and the presence of EBV DNA was confirmed by Southern blotting. Z-6,  Z-43, 
and 7_,55 cell lines constitutively produced 192, 48, and 78 U/ml LT, respectively, as assessed 
by a cytotoxicity assay and antibody neutralization. Levels of tumor necrosis factor (TNF) were 
undetectable. Scatchard analysis revealed that all the cell lines expressed high-af~nity TNF/LT 
receptors  with receptor densities  of 4197,  1258, and 1209 sites/cell  on Z-6,  Z-43,  and Z-55, 
respectively. Furthermore, labeled TNF binding could be reversed by both unlabeled TNF, as 
well as by LT. Studies with p60 and pS0 receptor-specific antibodies revealed that the three lines 
expressed primarily the p80 form of the TNF receptor.  When studied in a clonogenic assay, 
exogenous LT stimulated proliferation of all  three cell lines  in a dose-dependent fashion at 
concentrations ranging from 25  to 500 U/ml.  Similar  results were obtained with [3H]TdR 
incorporation. Monoclonal anti-LT neutralizing antibodies at concentrations of 25-500 U/ml 
inhibited cellular multiplication in a dose-dependent manner. It is interesting that in spite of 
a common receptor,  TNF (1,000 U/ml) had no direct effect on Z-55 cell growth, whereas it 
partially reversed the stimulatory effect of exogenous LT. In addition, TNF inhibited Z-6 and 
Z-43  cell  proliferation,  and its  suppressive  effect  was  reversed by exogenous LT.  Both pS0 
and p60 forms of soluble TNF receptors suppressed the lymphoblastoid cell line proliferation 
and their inhibitory effect was partially reversed by LT. Our data suggest that (a) LT is an autocrine 
growth factor for EBV-transformed lymphoblastoid B cell lines; and (b) anti-LT antibodies, soluble 
TNF/LT receptors,  and TNF itself can suppress the growth of lymphoblastoid cells, probably 
by modulating or competing with LT. It is therefore possible that soluble TNF/LT receptors, 
TNF, and anti-LT antibodies may be exploitable  for clinical trials  in disorders in which EBV 
has been implicated as an etiologic factor. 
E 
BV can infect and immortalize human B lymphocytes 
and, as a result, permanent lymphoblastoid cell lines are 
established  (1). EBV-carrying B cell lines may evolve from 
cells transformed in vitro (1) or from individuals who had 
a prior EBV infection (2, 3).  Although the mechanism by 
which these cells are immortalized is largely unknown, it 
has been shown that the cells contain most, if not all, the 
herpesvirus genome as a multicoFy episome (4), and that EBV, 
through expression of the full set of light virus-coded "la- 
tent" proteins, may protect human B cells from programmed 
cell death (apoptosis)  (5). 
Over the last several years it has become clear that a crit- 
ical event in the process of B cell immortalization by EBV 
is the establishment of an autocrine loop where the cells pro- 
duce a growth factor that supports their own proliferation 
(6-9).  Several molecules may contribute to this activity.  A 
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EBV-transformed B cell proliferation in an autocrine fashion 
(10-12).  Similarly,  affinity-purified soluble CD23,  a B cell 
activation antigen expressed at high levels in EBV-immortalized 
cells, which also functions as a low-affinity receptor for IgE 
(13,  14), was reported to promote growth in EBV-immor- 
talized B cells by some investigators (15) but not by others 
(16, 17). IL-6 has been found to contribute to up to 30% 
of the autocrine growth-stimulating activity in many EBV 
lymphoblastoid cell lines (18). Other investigators reported 
that normal human EBV-transformed B ceils constitutively 
produce IL-5 (19), and that II.,5 probably stimulates EBV- 
transformed B cell proliferation in an autocrine fashion (20). 
Recently, Pike et al. (21) have identified lactic acid as a soluble 
factor that promotes growth of EBV-immortalized B cells 
in serum-free conditions. 
Previously, we have reported the isolation of human lym- 
photoxin (LT)  1 from a lymphoblastoid cell  line (22,  23). 
Subsequently, we screened over 200 EBV-transformed human 
B cell lines and found that all lines without exception, pro- 
duce LT constitutively (Aggarwal B. B., unpublished data). 
The role of LT in these cells is not understood. It is known 
that recombinant LT enhances the proliferation of activated 
B cells and augments B cell proliferation induced by IL-2 (24). 
Furthermore, Seregina et al. (25) have recently reported that 
conditioned medium from a human lymphoblastoid B cell 
line RPMI-6410t that stimulated its own growth, contained 
a high concentration of LT. Although this study suggested 
that LT was an autocrine growth factor for EBV-immortalized 
B cells (25), another study showed that the EBV-transformed 
DUL lymphoblastoid cells were not affected by LT (26). We 
therefore analyzed LT expression and activity in three different 
lymphoblastoid cell lines recently established  in our labora- 
tory. We found that all three lines constitutively produce and 
secrete LT and express high-affinity LT receptors.  In addi- 
tion, their proliferation is stimulated by LT and inhibited by 
anti-LT neutralizing antibodies, soluble TNF/LT receptors, 
and TNF. 
Materials and Methods 
Cell Lines.  The EBV B ceU lines we studied arose spontane- 
ously from suspension cultures of bone marrow (BM) cells from 
three patients who had previously been infected with EBV. Z-6 
line was developed from BM cells of a 26-yr-old acute lympho- 
blastic leukemia patient whose BM ceils did not show any cyto- 
genetic abnormality; Z-43 cell line was established from marrow 
cells obtained from an 84-yr-old  patient who had refractory anemia 
with excess of blasts in transformation (RAEB-t) and a karyotype 
of 46, XX, t(3q;Sq); and Z-55 is a cell line derived from BM cells 
of an 80-yr-old patient with acute myelogenous leukemia whose 
blasts were diploid. This study was performed with informed con- 
sent and was approved by the Human Ethics Committee of our 
institution. 
1 Abbreviations used in this paper: BM, bone marrow;  J,, immunoglobulin 
heavy  chain  joining  region; LT, lymphotoxin;  RCV, relative  cell  viability; 
rh, recombinant human. 
Heparinized BM cells obtained from the three patients at diag- 
nosis were layered  over Ficoll-Hypaque  (Pharmacia  Fine Chemicals, 
Piscataway, NJ) and centrifuged (400 g, 4~  for 20 rain to remove 
neutrophils and RBCs. Low-density BM cells (106/ml) were cul- 
tured in RPMI-1640 (Gibco Laboratories, Grand Island, NY) sup- 
plemented with 10% FCS (Flow Laboratories,  Inc., McLean, VA). 
Cultures were maintained in 25- or 75-cm  2 tissue culture flasks 
(Becton Dickinson & Co., Oxnard, CA) and were fed by replace- 
ment of 80% of the medium with an equal volume of fresh com- 
plete medium every 3 d for several months. Cells from the estab- 
lished lines were maintained in logarithmic growth before testing. 
Cell density was decreased to 2-5  x  105 cells/ml and culture 
medium was exchanged every 24 h. Viability was assessed using 
the try'pan blue exclusion test. Cytospins were.  stained with May- 
Grunwald Giemsa for morphological analysis. 
LT, TNE Anti-LT Neutralizing Antibodies, Anti-TNF Receptor An- 
tibodies, and Soluble TNF Receptors.  Recombinant human (rh) LT 
(sp act 5  x  107 U/rag) and monoclonal anti-LT neutralizing an- 
tibodies were generously provided by Genentech, Inc. (South San 
Francisco, CA). rhTNF-c~ (sp act 2  ￿  107 U/rag) was purchased 
from Boehringer Mannheim Biochemicals  (Indianapolis, IN). An- 
tibodies against the p60 and pS0 forms of the TNF receptor were 
developed in a rabbit injected with purified recombinant forms of 
these proteins (27). The antibodies were purified by affinity chro- 
matography.  Soluble  TNF receptors (p60 and p80) produced  in Esch- 
erichia coli were kindly provided  by Dr. T. Kohno (Synergen  Corp., 
Boulder, CO). 
Immunophenotype Analysis.  The mAbs used to determine im- 
munophenotype were anti-CD2, CD3, CDT, CD9, CD10, CD13, 
CD14, CD19, CD20, CD21, CD22, and CD33, all of which were 
obtained from the Becton Dickinson monodonal center (Moun- 
tain View, CA), except anti-CD9 mAb 50N19 which was kindly 
provided by B. M. Longsnecker  (University of Alberta, Edmonton, 
Alberta, Canada). Staining of the leukemia cells (5  x  1@ ceIls/ml) 
followed previously described procedure (28, 29)  and isotype- 
identical nonreactive  mAbs were used as negative controls. Stained 
cells were analyzed on a dual-beam cytofluorograph (System  50H; 
Ortho Diagnostics Systems, Westwood, MA). 
Cytogenetic Analysis.  Z-6,  Z-43, and 7_,55 ceils were fed with 
fresh RPMI-1640 medium supplemented with 20% FCS 24 h be- 
fore harvesting. Cells were then spun down and exposed to hypo- 
tonic solution (0.06 M, KC1) for 10 min at room temperature. After 
centrifugation at 1,700 rpm for 5 rain, the supematant was dis- 
carded, the cell pellet was fixed  in a mixture of methanol and acetic 
acid (3:1 by volume), and washed three times with a fixative.  Fixed 
cells were dropped on glass slides, and air-dried  chromosome prepa- 
rations were made. 5-6-d-old slides were G-banded following the 
routinely used technique (30). 50 G-banded  metaphase spreads from 
each cell line were evaluated  under the microscope  and 7-10 karyo- 
types were prepared using  the  automatic  karyotyping  system 
(Genetiscan; PSI, Houston,  TX). 
DNA Analysis for Immunoglobulin Heavy Chain Joining  Region 
(J,) Rearrangement and for the Presence of EBV.  DNA was prepared 
by proteinase K (Bethesda Research Laboratories, Bethesda, MD) 
digestion in SSCE buffer (0.15 tool/liter sodium chloride, 0.015 
tool/liter sodium citrate, 0.01 tool/liter EDTA). 15 ~g of DNA 
from each cell line were digested with restriction endonucleases 
under conditions recommended  by the supplier (International Bin- 
technologies, Inc., New Haven, CT), electrophoresed on 0.8% 
agarose gel, blotted, and hybridized as described (31). The probes 
were labeled by oligoprimer extension to a sp act of 1-3  x  109 
cpm/Izg of DNA (32). After hybridization, the filters  were washed 
at 60~  for 60 rain with a solution of 0.1  x  SSC (lx  SSC  = 
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autoradiographed. The probes used were the following: H-a 2.9 
kb Hind III/EcoKI insert (kindly provided by Dr. A. Deisseroth, 
M.  D. Anderson Cancer Center) for the J. rearrangement, and 
EBV 5.0-kb segment containing the coding region for the nuclear 
antigen-1 (generously provided by Dr. J. Hearing, State University 
of New York, Stony Brook, NY) (33). 
LT and TNF Bioassays.  Mouse connective tissue cell line 1.,929 
(CCL 1) was obtained from American Type Culture Collection, 
(Kockville, MD). 
TNF secretion  by B lymphoblastoid  cells was determined in cul- 
ture supematants, using bioassay  as previously  described  (34). Briefly, 
0.2  x  105 cells in 0.1 ml of the MEM medium containing 10% 
FCS, glutamine (2 mM), penicillin (500 U/ml), and gentamycin 
(5 #g/ml) were plated in 96-well plates (Falcon Labware, Oxnard, 
CA). After overnight incubation, media was removed and a serial 
dilution of the test sample along with actinomycin D (1 #g/ml) 
was layered  in a total final volume of 0.1 ml, and then the incuba- 
tion at 37~  was continued for the next 18 h. Thereafter, the media 
was removed and viable cells were monitored by crystal violet 
staining according to the procedure as described (22). The plates 
were read for optical density by an autoplate reader. Percent rela- 
tive cell viability (KCV) was calculated as optical density in the 
presence of LT/TNF as test sample divided by optical density in 
the absence  of test sample (media) multiplied  by 100. 1 U of  TNF/LT 
was the amount needed for 50% KCV. For neutralization of bio- 
logical  activity, test  sample was  incubated  with the  TNF  or 
LT-specific antibodies (35) for 30 min at 37~  and then assayed 
for remaining activity by the bioassay. 
Radioreceptor Assay.  Receptor binding assays  were carried out 
essentially as previously described (27, 36). TNF was labeled with 
Na12SI using the Iodogen method  as described previously (36). 
Briefly, 10 #g of TNF in a 20 #1 volume was placed onto a film 
of 50/~g of Iodogen and incubated for 10 min at 4~  in the pres- 
ence of I mCi of carrier-free NamI. Free iodine was removed by 
gel filtration on a PD-10 (Sephadex G-25; Pharmacia  LKB Biotech- 
nology AB, Uppsala, Sweden) column equilibrated with PBS con- 
taining 0.1% gelatin. More than 96% of the iodine in the final 
product was incorporated into the protein as determined by TCA 
precipitation. The specific  activity of the labeled  TNF ranged from 
20 to 30 mCi/mg. Standard binding assays  were performed in flex- 
ible 96-well plates precoated with 0.2 ml of FCS for 24 h at 4~ 
The binding  medium (R.PMI-1640) contained 10%  FCS. Cells 
(106/0.1 ml) were incubated with increasing amounts of mI-TNF 
in the absence (total binding) or presence of 1,000 nM unlabeled 
ligand (nonspecific binding) for 90 min at 4~  The cells were 
washed three times with ice-cold medium (PBS containing 0.1% 
BSA) at 40C, and the cell-bound radioactivity was determined in 
a gamma-counter (Cobra-Auto-Gamma, Packard Instrument Co., 
Meriden, CT).  Each determination was performed in triplicate. 
Specific binding of the 12SI-labeled  TNF was calculated by subtrac- 
tion of nonspecific  binding from the total binding. The dissocia- 
tion constant (Kd) and the number of receptors were obtained by 
Scatchard analysis (37). 
Clonogenic Assay.  The clonogenic assay  was performed as pre- 
viously  described (38). B lymphoblastoid  cells  were cultured in 0.8% 
methylcellulose  (Fluka Chemical Corp., Ronkonkoma, NY), 10% 
FCS (Flow Laboratories) and alpha medium (Gibco Laboratories, 
Inc.) at 2-4  x  104 cells/ml. The culture mixture was placed in 
35-mm petri dishes (Nunc Inc., Naperville, IL) in duplicate and 
maintained at 37~  with 5%  CO2 in  air in  a humidified at- 
mosphere. Colonies were counted after 7 d using an inverted mi- 
croscope. A colony was defined as a cluster of more than 40 cells. 
Thymidine Incorporation Assay.  This assay was carried out es- 
sentially according to a previously  described  procedure (39). To de- 
termine the effect of human LT, cells (10  x  103/well) were plated 
in 0.2 ml of the medium (RPMI-1640 plus 10% FCS) in 96-well 
plates (Falcon Labware) along with variable concentrations of LT. 
After 5 d of incubation, [3H]TdR.  incorporation was examined. 
During the last 6 h, [3H]TdR (6.7 Ci/nmol; New England Nu- 
clear, Boston, MA) was added to each well (0.5 gCi/well). There- 
after, cells were harvested with the aid of a cell harvester (PHD; 
Cambridge  Technology, Inc.,  Watertown,  MA)  and  lysed by 
washing with distilled water. Radioactivity bound to the filter was 
measured in a liquid scintillation  counter (Model 1600 TK; Packard 
Instrument Co.). Each determination was made in five replicates. 
Results 
Cell Characterization Studies.  The three lines were charac- 
terized by morphological, immunophenotypical, cytogenetic, 
and receptor binding studies.  All cells from our three cell 
lines have lymphoblast morphology. Their doubling time in 
liquid culture is '~24 (Z-6),  16 (Z-43), and 12 h (Z-55). The 
cells form dusters that can be easily broken by repeated pipet- 
ting and if left in culture, dusters would be formed again. 
All cell  lines  were  mycoplasma-free, as  tested by a  rapid 
mycoplasma detection system (Gen-Probe, San Diego, CA). 
Immunophenotype studies revealed that the three cell lines 
expressed B cell (CD9, CD10, CD19, CD20, CD21, CD22) 
but not T cell (CD2, CD3, CD7) or myeloid (CD13, CD14, 
CD33) surface antigens (Table 1), indicating that Z-6, Z-43, 
and Z-55 are B cells. It is interesting that CD21, which is 
expressed in the three cell lines, is a receptor for the gp350/220 
envelope  glycoprotein of EBV  (40,  41). 
Cytogenetic analysis showed that the lymphoblastoid cell 
line 7_,6 was exclusively tetraploid, and not a single metaphase 
cell showed near-diploid or diploid chromosome constitu- 
tion. Giemsa-banding pattern revealed a male XY chromo- 
some constitution with only three copies of chromosome 6 
and a translocation between the lq and 15q. This only sub- 
metacentric marker chromosome was of the morphology of 
a chromosome No. 2. A typical G-banded karyotype showing 
this marker chromosome from three additional cells is shown 
in Fig. 1 a. In cell line Z-43, the stem line chromosome number 
varies from 46 to 48. The Giemsa-banding pattern revealed 
three cell populations with respect to both structural and nu- 
merical chromosome abnormalities. A derivative chromosome 
No. 2 was present in every metaphase spread with the XX 
sex chromosome constitution. The distal end of the q arm 
of this chromosome 2 was replaced by an unidentified chro- 
mosome segment. Other cell populations have either trisomy 
of chromosomes 12, 15, or both. A typical G-banded karyo- 
type of this cell line is shown in Fig. 1 b. All of these abnor- 
malities, individually or in combination, are donal. Lympho- 
blastoid cell line Z-55 showed 47 chromosomes in all metaphase 
spreads.  Giemsa-band analysis revealed complete or partial 
trisomy of  chromosome 3 and an XY chromosome constitu- 
tion (Fig.  1 c). There were three types of metaphases with 
respect to chromosome 3 abnormalities.  One third of the ceils 
had complete trisomy of chromosome 3, and another one- 
third cell population had partial trisomy of chromosome 3, 
765  Estrov  et al. Table  1.  Surface  Marker Analysis  of the B  Lymphoblastoid  Cell Lines 
Percent  positive cells 
Cell line  CD2  CD3  CD7  CD9  CD10  CD19  CD20  CD21  CD22  CD13  CD14  CD33 
Z-6  0  8  0  53  5  94  94  87  15  0  0  0 
Z-43  0.3  0  0  51  13  82  91  56  28  0  0  0.9 
Z-55  0  5  4  48  9  81  89  60  38  0  0  2 
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Figure  1.  (a) A G-banded karyo- 
type from the cell line Z-6 showing 
tetraploid  chromosome  constitu- 
tion. Only chromosome 6 is present 
in three copies. A translocation  in- 
volving the long arm  of chromo- 
some 1 and the long arm of 15 is 
a characteristic  feature of this  cell 
line. (Bottom) This marker chromo- 
some  from  three  additional  met- 
aphase spreads is shown (arrows).  (b) 
A G-banded  karyotype  of the cell 
line Z-43 showing a derivative chro- 
mosome No. 2 (arrows) and triso- 
mies of  chromosomes 12 and 15. All 
other chromosomes appear to have 
normal G-banding  pattern  and are 
present  in disomic  form. (Bottom) 
Derivative  and  a normal  chromo- 
some 2 and trisomies of 12 and 15 
from another metaphase spread. (c) 
A G-banded karyotype of a cell from 
the cell line Z-55 showing partial 
trisomy of chromosome 3 and the 
XY chromosome constitution. All 
other autosomes are present in two 
copies each with a normal banding 
pattern.  (Bottom) Two karyotypes 
showing complete trisomy of chro- 
mosome 3  and  partial  trisomy of 
No. 3 with a translocation  in the 
short  arm  from  two  additional 
metaphase  spreads. Figure  2.  (a) Southern  blot of  DNA digested  with EcoKI  and 
hybridized with a J. probe. (Lane I) Z-43 cells; (lane 2) acute 
lymphoblastic leukemia patient; (lane 3) 7_,55 cells; (lane 4) 7_,6 
cells; (lane  5) HI~60  cells  (acute  promyelocytic  leukemia  cell  line); 
(lane 6) chronic  myelogenous  leukemia  patient. The germline po- 
sition for the J. band is seen in lanes 5 and 6. (b) Southern blot 
of  DNA digested  with EcoRI  and hybridized  with an EBV probe. 
(Lane I) Z-43 cells; (lane 2) Z-6 cells; (lane 3) Z-55 cells; (lane 
4) HL-60 cells (acute promyelocytic  leukemia cell lines). 
and a third chromosome 3 was deleted in the short arm. The 
short  arm  of the extra chromosome  3  was replaced by an 
unidentified segment with two distinct bands. All other chro- 
mosomes showed normal G-banding patterns. In conclusion, 
the lymphoblastoid cell lines (7_,6, 7_,43, and 7_,55) have their 
own chromosomal  characteristics  and can be easily distin- 
guished  from each other.  Two of them  are of male origin 
(7_,6 and 7_,55) and  the  third  of female origin  (Z-43). 
To establish that these are monoclonal B cell lines,  we per- 
formed a DNA analysis  of their JH.  In all  three lines,  rear- 
ranged  J. bands  were found by Southern  blot  analysis  of 
DNA digested with HindlII, EcoRI, and BamHI restriction 
enzymes.  The  rearranged J. bands  were of distinct  size  in 
each of the cell lines. Southern blot analysis of DNA digested 
with EcoRI is depicted in Fig. 2 a. DNA from a patient with 
acute lymphoblastic leukemia was used as a positive control 
(Fig.  2 a,  lane 2),  and DNA from HI.-60 cells  and from a 
patient with chronic myelogenous leukemia were used as nega- 
tive controls. Lanes  I  (Z-43), 2  (Z-55), and 4 (Z-6  i  show J. 
rearrangement.  These results prove that each line is a mono- 
clonal B  cell line. 
The presence of EBV was demonstrated in these cell lines 
by Southern blotting as demonstrated in Fig. 2 b. The DNA 
of the cell lines was digested with EcoRI and hybridized with 
an EBV probe.  Lanes  1 (Z-43), 2  (Z-6),  and 3  (7_,55) show 
detection of EBV DNA. Lane 4 is a negative control of HI: 
60 cells. 
All Three Cell Lines Produce  LT and Express TNF/LT Recep- 
tors.  The requirements that must be fulfilled for a given mol- 
ecule to act as an autocrine growth factor include the capa- 
bility of the cell to produce the cytokine,  the presence of 
cytokine receptors on the surface of the cell,  the ability of 
a cell to proliferate in response to the specific cytokine, and 
finally inhibition  of cell growth by antibodies against  that 
cytokine. 
The supernatants from all three cell lines employed in these 
studies were examined for their ability to constitutively se- 
crete LT and TNF. The results of these experiments are shown 
in Table 2.  All the  three cell lines  were found to produce 
LT and not TNF.  The levels of LT secreted by 7_,6 cell line 
(192  U/ml)  were significantly higher  than  those produced 
by 7_,55 (78 U/ml)  or Z-43 (48 U/ml).  Besides producing 
767  Estrov  et al. Table  2.  Constitutit~e  Production of TNF and LT from 
B Lymphoblastoid Cell Lines 
Cell line  TNF/LT U/ml  TNF  LT 
Z-6  192  -  +  + 
Z-43  48  -  +  + 
Z-55  78  -  +  + 
Cells (106 cells/ml) were cultured for 72 h at 37~  and then the condi- 
tioned media was analyzed for the cytotoxic factor on actinomycin D treat- 
ed L-929 cells according to the procedure as described  (22). Anti-LT and 
anti-TNF antibodies were used to distinguish between TNF and LT. All 
determinations were made in duplicate. 
LT, we found that all three cell lines expressed the receptors 
for TNF/LT (Fig. 3). All cell lines bound labeled TNF, and 
a saturating binding was observed that could be reversed with 
unlabeled TNF (top). The highest amount of TNF binding 
occurred with Z-6 cell line, whereas binding with Z-43 and 
7__,55 was very similar. Scatchard analysis (bottom) revealed high- 
affinity binding with receptor density of 4197, 1258, and 1209 
sites/cell  on Z-6, Z-43,  and 7_,55 cell lines,  respectively. It 
is interesting that a large number of binding sites per cell 
on Z-6 cell line corresponded with the higher amount of LT 
production. 
Previously, our laboratory has shown that both TNF and 
LT share a common receptor on certain cell types (42).  We, 
therefore, examined whether these cells express receptors that 
bind both LT and TNF. The results of these experiments are 
shown in Fig. 4.  It is clear that labeled TNF binds to all 
three cell lines and that its binding can be displaced by both 
unlabeled TNF and LT, thus suggesting a common receptor 
for the two cytokines. 
Recently, two different receptors for TNF/LT have been 
identified with a molecular mass of 60 and 80 kD (43-50). 
The 60-kD receptor, which is expressed primarily on epithe- 
lial cells, has been shown to be involved in the antiprolifera- 
tive effects of TNF/LT,  whereas the 80-kD  form of the 
receptor, which is expressed mainly on myeloid ceils, has been 
shown to transmit proliferative signals in certain cell types 
(51). In our studies, therefore, we also examined the type of 
receptor expressed by our lymphoid cell lines.  The results 
of these experiments are depicted in Fig. 5. These results show 
that antibodies specific for the p60 form of the receptor are 
unable to block the binding of TNF, whereas the binding 
is completely blocked by antibodies to the p80 form of the 
TNF receptor, indicating that these ceils express only the p80 
form of the TNF receptor. No receptor blocking was ob- 
served with the preimmune serum. 
Effect of LT on B Lymphoblastoid Cell Proliferation.  Since 
we found that  our cell lines  produce LT  and express  LT 
receptors, we investigated the effect of exogenous and en- 
dogenously produced LT on these lymphoblastoid cell prolifer- 
ations. Addition of exogenous LT stimulated Z-6, Z-43, and 
Z-55  cell multiplication in a dose-dependent fashion as as- 
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Figure 3.  Saturation of specific binding of nSI-TNF to our B lympho- 
blastoid cell lines.  106 cells were incubated with increasing amounts of 
nSI-TNF-ot in the presence or absence of 1,000 nM unlabeled ligand for 
90 min at 4~  in a total final volume of 0.1 ml as described  in Materials 
and Methods. (Tbp) Specific binding plotted as a function of concentration 
of the labeled  ligand; (bottom) results of Scatchard  analysis. Each point 
represents the mean of three determinations. 
sessed by a donogenic assay at concentrations ranging from 
25 to 500 U/ml, by up to 100,  150, and 75%, respectively 
(Fig. 6). A similar but less significant stimulatory effect was 
found with a well-established EBV B line that was used as 
control. LT stimulated Raji cell proliferation,  however, in con- 
trast to our recently established lines, Raji cell growth plateaned 
at 100 U/ml (Fig.  6).  Similar results were obtained in the 
thymidine incorporation assay. Addition of LT at concentra- 
tions ranging from 25 to 1,000 U/ml increased cellular thymi- 
dine incorporation in Z-6 cells, in a dose-dependent manner 
by up to 65%  (Fig.  7). 
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Figure  4.  Displacement  of TNF binding by LT on the three B lym- 
phoblastoid  cell lines. 104 cells were incubated  with I~I-TNF-c~ (0.5  x 
10~ cpm) in the presence or absence of 400 nM unlabeled either TNF or 
LT for 90 minat 4~  in a total final volume of 0.1 ml as described in 
Materials and Methods.  Each point represents the mean of three determi- 
nations. 
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Figure  6.  Effect of LT on Z-6, Z-43, Z-55, and Raji cell proliferation. 
Cells were plated in a clonogenic assay as described in Materials and Methods. 
Data are presented  as means  _+  SD of percent  control colony numbers 
grown in the absence of exogenous LT. Data of duplicate cultures  from 
two separate experiments  of each of the cell lines are presented.  Means 
of colony numbers in control duplicate dishes of Z-6 were 186 and 223; 
of 7_,43 were 359 and 436; of Z-55 were 546 and 659; and the means of 
colony numbers of Raji cells were 702 and 682. 7_,6, Z-43, and Z-55 were 
plated at a density of 4  x  104 ceUs/ml and Raji cells at a density of 2  x 
104 ceUs/ml. Raji cells-an EBV B lymphoblastoid cell line (2)-were ob- 
tained from the American Type Culture Collection (Rockville, ME)) and 
used  as control. 
These results indicated that LT stimulates proliferation of 
the B cell lines.  However,  our data also indicate  that  these 
cells constitutively produce LT. We, therefore, examined the 
effect of antibodies against LT on these EBV B cell lines. Anti- 
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Figure  5.  Inhibition of TNP binding to B lymphoblastoid  cell line z-6 
by antibodies  specific for two different types of TNF receptors.  106 cells 
were incubated  with nSI-TNF-o~ (0.5  x  106 cpm) in the absence (total 
binding) or presence of either 400 nM unlabeled TNF (nonspecific binding) 
or 2.4/zg/ml anti-p60 (p60 receptor) or 2.4/zg/ml anti-80 (p80 receptor) 
antibodies for 90 rain at 4~  in a total final volume of 0.1 ml as described 
in Materials and Methods.  Each point represents the mean of three deter- 
minations. 
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Figure  7.  Effect of different concentrations  of lymphotoxin on thymi- 
dine incorporation by human B lymphoblastoid  cell line Z-6. Cells (104) 
were incubated  with different combinations  of human LT in a total final 
volume of 0.1 ml for 5 d at 37~  During the last 6 h, cells were pulsed 
with thymidine (0.5/~Ci) and incorporation determined  as described in 
Materials and Methods.  Each point represents the mean of five determi- 
nations. 
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blastoid cell proliferation (Fig. 8). Increasing concentrations 
of anti-LT antibodies suppressed Z-43 and Z,55 colony growth 
in a dose-dependent manner. The inhibitory effect of the neu- 
tralizing antibodies was partially reversed by a low concen- 
tration of LT which did not affect cell growth (Fig. 9), sug- 
gesting  that  endogenously produced LT may stimulate B 
lymphoblastoid ceil growth in an autocrine fashion. 
Effect of TNF on Z-6, Z-43, and Z-55 Cell Proliferation.  Be- 
cause TNF and LT share the same receptors (42) even in our 
ceil lines as indicated above, we therefore evaluated the effect 
of TNF on the proliferation of the B cell lines. TNF (1,000 
U/ml) inhibited Z-6 and 7_,43 cell proliferation by 32 and 
37%, respectively (68  _+ 8 and 63  +  7% control), whereas 
it had no effect on 7-,55 cell growth (99 +  5% of mean colony 
numbers in control cultures).  LT partially (Z-6)  and com- 
pletely (Z-43) reversed the suppressive effect of TNF. How- 
ever, TNF partially suppressed the stimulatory effect of LT 
on Z-55 cells (Fig.  10). 
Effect of  Soluble TNF Receptors on Lymphoblastoid Cell Prolifer- 
ation.  TNF soluble receptors are important cytokines that 
may serve as naturally occurring inhibitors of both LT and 
TNF. We therefore investigated their effect on the three EBV 
B lines. Both p60 and p80 soluble TNF receptors inhibited 
the three cell lines' proliferation (Fig.  11) by 48 and 45% 
(2-6), 41 and 20% (2-43), and 30 and 54% (2-55), respec- 
tively, at a concentration of 0.1 rag/m1. LT (100 U/ml) par- 
tially reversed the suppressive effect, thus proving its specificity. 
Discussion 
TNF and LT (also termed TNF-/3) are polypeptide hor- 
mones that share a 30% sequence homology and possess mul- 
tiple biological activities, many of which overlap to various 
degrees (52-62). Unlike TNF, which is produced by different 
ceils including macrophages (54, 62), lyrnphocytes, Kupffer's 
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Figure  8.  Effect of anti-LT neutralizing antibodies on Z-43 and Z-55 
colony proliferation. Data from two separate  experiments are presented 
as means  +  SD of percent of control colony numbers. Means of colony 
numbers in control duplicate cultures of Z-43 were 225 and 341, and of 
7_,55 were 456.5 and 597. 
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Figure  9.  Effect of anti-LT neutralizing antibodies on Z-6 cell prolifer- 
ation. Data are presented as means  +  SD of total colony numbers from 
two identical experiments. 
cells, smooth muscle cells, and other cells (62), the produc- 
tion of LT is restricted to lymphocytes or cells derived from 
lymphoid progenitors (62-65). Because human LT was first 
isolated from a lymphoblastoid cell line (22, 23), and since 
all lymphoblastoid B cells that we tested constitutively pro- 
duce LT (Aggarwal, B. B., unpublished data), we investigated 
the role of LT in different EBV-infected lymphoblastoid B 
cell lines. These lines originated from BM low-density cells 
of leukemia patients who had an EBV infection before diag- 
nosis of leukemia. The three cell lines had a karyotype that 
was different from the patient's leukemic cells and they ex- 
pressed B cell, but not T  cell or myeloid surface markers. 
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Figure  10.  Effect of TNF on Z-6,  Z-43,  and Z-55 call proliferation. 
Data from two separate experiments on each cell line are presented as per- 
centage of change in colony growth. Mean numbers of colonies in control 
cultures of Z-6 were 303 and 287;  of Z-43 were 1591 and 522;  and of 
7_,55 were 568 and 1503. TNF was added to culture at a concentration 
of 1,000 U/ml, and LT was added at a concentration of 100 U/ml. 
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Figure 11.  Effect  ofsolubh TNF receptors  (p60 and p80) on Z-6, 7_,43, 
and Z-55 cell  proliferation.  Data from  two separate  experiments  are presented 
as percentage  of change  in colony  growth. Mean numbers  of colonies in 
control cultures of Z-6 were 125 and 131; of Z-43 were 1218 and 1710, 
and of  Z-55 were 1223 and 1268. LT was added to culture  at a concentra- 
tion of 100 U/ml, whereas  p60 and p80 soluble  TNF receptors  were  added 
at 0.1 mg/ml. 
In all  three lines we found rearranged J, bands  and EBV 
DNA. Supernatant obtained from all the lines contained high 
concentrations of LT, but not TNF when studied in our bio- 
assay. The latter results agree with a previous report (25). 
All three of our lymphoblastoid cell lines expressed high- 
affinity TNF/LT receptors. Labeled TNF binding could be 
reversed by both unlabeled TNF as well as LT, thus providing 
its specificity. Recently, two immunologically distinct TNF 
receptors with approximate molecular masses of 60 (p60) and 
80 kD (pS0) have been identified (43-49). Both receptors are 
expressed to varying degrees in different cell types, and both 
TNF and LT bind to these receptors (59, 60).  We used anti- 
p60 and anti-pS0 antibodies to determine the presence of these 
receptors in our lines,  and found that the three cell lines ex- 
press mainly the p80 type of TNF/LT receptor. We then tested 
the effect of LT on these B lymphoblastoid cells. Addition 
of exogenous LT exerted a stimulatory effect on the three 
lines in a dose-dependent manner. Anti-LT neutralizing an- 
tibodies significantly inhibited the growth of cells, and this 
suppressive effect was partially reversed by exogenous LT. These 
results suggest that the autonomously produced LT serves 
as a growth factor in these EBV-infected B cells and stimu- 
lates their growth in an autocrine fashion. 
Since both  TNF  and LT share common receptors,  and 
because TNF was reported to either inhibit (66) or stimulate 
B cell proliferation (67-69), we studied the effect of this cy- 
tokine  in  our  cell lines.  TNF  exerted a  mild  inhibitory 
effect on Z-6 and Z-43 cells,  and its suppressive  effect was 
reversed by exogenous LT. However, TNF at a concentration 
of 1,000 U/ml had no effect on Z-55 colony proliferation, 
whereas exogenous TNF partially reversed the stimulator)' 
effect of LT. These results reflect a possible competitive inter- 
action between TNF and LT, whereas both bind to the same 
receptors (42). 
We then studied the effect of soluble TNF receptors on 
our B lymphoblastoid cell lines. Truncated fragments of the 
extracellular domains of the TNF receptors initially desig- 
nated TNF-binding proteins, have been found in human serum 
and urine (42-50, 70-73). These TNF-binding proteins bind 
both TNF and LT and inhibit the effects of TNF on target 
cells in culture (43,  72,  73).  We found that both p60 and 
pS0 soluble TNF receptors inhibited B lymphoblastoid cell 
proliferation and that LT reversed their inhibitory effect. 
EBV infects more than 90%  of the human population 
worldwide and persists for life in infected hosts (74).  Upon 
primary infection, EBV may cause infectious mononucleosis, 
a self-limiting lymphoproliferative disorder (75-77). It is im- 
portant that EBV also has been associated with certain malig- 
nant disorders such as undifferentiated nasopharyngeal carci- 
noma, Burkitt's lymphoma, and Hodgkin's disease (78-82). 
Highly lethal EBV-associated  lymphoblastoid diseases have 
been described in severe congenital or acquired immunode- 
ficiency (78, 83, 84), and in recipients of BM transplantation 
(78, 83, 85). Moreover, recent reports suggest that lymphomas 
complicating AIDS may be induced by EBV (84),  and that 
EBV may be implicated in the pathogenesis of angioimmuno- 
blastic lymphadenopathy and angioimmunoblastic lympha- 
denopathy-like lymphoma (86, 87).  The mechanism under- 
lying the aberrant lymphoproliferative stimulus induced by 
EBV is unclear. 
Our investigations demonstrate that LT stimulates EBV- 
infected B cells in an autocrine fashion. Anti-LT neutralizing 
antibodies and soluble TNF receptors inhibit their prolifera- 
tion by either binding and neutralizing LT, or by preventing 
the interaction between LT and its receptors. It is therefore 
possible that these molecules may have salutary effects in EBV- 
associated disorders, and their usefulness merits exploration 
in future therapeutic trials. 
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